Celebrate SMA Awareness with us!  Stuart Peltz (Founder and CEO, PTC Therapeutics) shares his perspectives on the dynamics of R&D in the context of the journey that led to the accelerated approval this August of  Evrysdi™ (risdiplam), the first oral treatment for SMA. What can we learn from the collaborative partnership between Roche, PTC Therapeutics, and the SMA Foundation?